The popular diabetes drug rosiglitazone, marketed as Avandia, more than doubles the long-term risk of heart failure and increases the long-term risk of heart attack by 42 percent, according to a new analysis.
Rosiglitazone initially came under scrutiny earlier this year when an analysis of short-term trials found a 43 percent increase in risk of heart attack among people taking the drug (SN: 6/23/07, p.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.